CK0804 (Allogeneic Regulatory T-cell Therapy)

Current understanding

To be populated as evidence accumulates.

May 17, 20 — MPN | Tumor | CURE: cross-connection with ck0804-cell-therapy-mf: Both slugs appear to describe the same CK0804 allogeneic regulatory T-cell program for myelofibrosis; the FDA orphan designation applies to both entries and they may warrant consolidation. (novelty: 3)
2026-01-06 — Key Oncology Drugs Granted FDA Designations in January 2026: FDA granted orphan drug designation (January 2026) based on reported reductions in spleen volume, symptom burden, and transfusion burden in heavily pretreated myelofibrosis patients (regulatory announcement; underlying trial data not yet peer-reviewed). (novelty: 4)